clinical trial · NCT06504862
A Study in Healthy Men to Test Whether Zongertinib Influences the Amount of 4 Other Medicines (Dabigatran, Rosuvastatin, Metformin, and Furosemide) in the Blood
Boehringer Ingelheim·phase1·completed·n = 32
HealthyZongertinibDabigatran-etexilateRosuvastatinMetformin hydrochlorideFurosemide
brief summary
For Part 1 of the trial, the main objective is to assess the effect of a single dose of zongertinib on the pharmacokinetics of a single dose of dabigatran-etexilate. For Part 2 of the trial, the main objective is to assess the effect of zongertinib at steady-state on the pharmacokinetics of a single dose of rosuvastatin, metformin and furosemide (administered as a cocktail).
started
Aug 20, 2024
primary completion
Oct 3, 2024
completion
Dec 18, 2024
last updated
Jan 9, 2026
official title
The Effect of Zongertinib on the Pharmacokinetics of Dabigatran (Part 1) and Rosuvastatin, Metformin and Furosemide Administered as a Cocktail (Part 2) in Healthy Male Subjects (a 2-part, Open-label, 2-period, Fixed-sequence Cross-over Trial)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol